Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 1997

View Archived Issues

Synthetic retinoids with anticoagulant effects

SDZ-MRL-953 prevents sepsis in cancer patients

Preclinical profile of Ono-1101 published

SciClone issued European patent for use of thymosin alpha 1 for hepatitis C

Matrix discontinues U.S. development of AccuSite

Biomira reports phase II results for cancer vaccine

Preclinical studies show broad antiseizure properties of ganaxolone

Oncologic Drugs Advisory Committee meets this week

LG Chemical licenses thrombin inhibitor to Warner-Lambert

NC-1800 now in phase II development

Chugai accelerates R&D outside Japan

Pharmacological characterization of BIBU-52

Kirin's TPO enters phase II in several Asian countries

Kyowa Hakko antiparkinsonian enters phase II trials

Amphetamines may provide long-term benefit in patients with ADHD

MIT licenses drug discovery technology to Dyax

Benefits of magnesium sulfate investigated in patients with unstable angina

Cytel and Searle to collaborate on cancer therapies

Myocardial and cerebral vasodilating effects of BMS-180448 in animals

Molecumetics and Teijin begin oral thrombin inhibitor collaboration

Potent GH secretagogues synthesized at Merck & Co.

Gene Logic and Japan Tobacco enter genomic alliance

Novel antibacterial agents from R.W. Johnson

Novartis evaluates SDZ-267-489 and analogues for increasing HDL cholesterol

Cardiovascular effects of SB-209509 and sumatriptan compared in dogs

Hormone therapy vs. simvastatin for hypercholesterolemia in postmenopausal women

Novel neuroprotective agent developed at Takeda

Mitsubishi describes synthesis and activity of MKC-242

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...